Progressive endothelial dysfunction and endothelial-to-mesenchymal transition in cerebral cavernous malformations
This study demonstrates that progressive endothelial dysfunction and an endothelial-to-mesenchymal transition (EndMT)-like phenotype are shared pathological features in both familial and sporadic cerebral cavernous malformations, validating patient-derived endothelial models for investigating disease mechanisms and therapeutic strategies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Inside the brain, a network of tiny blood vessels delivers oxygen and nutrients to every cell. These vessels are lined with a single layer of cells called endothelial cells, which act as a living seal, keeping blood contained and preventing leaks. When this lining breaks down, the vessels become fragile and prone to leaking blood into the brain tissue, causing strokes, seizures, or severe headaches. This is the reality for people with cerebral cavernous malformations, a condition where clusters of these weak, dilated vessels form dangerous lesions. While some people are born with a genetic flaw that predisposes them to these lesions, others develop them spontaneously later in life. For decades, doctors and scientists have struggled to understand exactly how a healthy blood vessel turns into a fragile, leaking one, and whether there is a way to stop or reverse the process before a hemorrhage occurs.
A team of researchers in Spain has taken a closer look at this transformation by studying the actual cells from patients. They focused on two distinct groups: families where the condition runs in the blood, and individuals who developed the lesions on their own. By growing cells from the blood of family members and from the surgical removal of the lesions themselves, the scientists were able to watch the disease unfold in a dish. They discovered that the problem begins long before a visible lesion appears. Even in people who carry the genetic mutation but have not yet developed a cavernous malformation, their blood vessel cells show signs of weakness. These cells struggle to move, fail to form proper networks, and begin to lose their identity. As the disease progresses, the cells undergo a dramatic change, shifting from a stable, flat shape designed to line a vessel into a long, wandering shape that resembles a different type of tissue entirely. This shift, known as endothelial-to-mesenchymal transition, essentially strips the cells of their ability to hold blood in place, leading to the formation of the fragile, leaky clusters seen in the brain.
The researchers examined cells from three siblings in a family with a history of the disease. Two of the siblings carried a specific genetic mutation, while the third did not. Even though the two carriers had not yet developed visible lesions, their blood vessel cells behaved differently from the healthy sibling's cells. One of the carriers showed a much more severe disruption than the other, suggesting that other genetic factors in the body can make the condition worse or better. The cells from the carrier with the more severe disruption were elongated and struggled to form the tube-like structures that healthy vessels need to function. They also moved poorly, failing to close gaps when the researchers scratched them, a test that mimics how vessels repair themselves after injury. This confirmed that the genetic mutation alone is enough to weaken the vessel lining, even before a full-blown lesion forms.
When the team looked at cells taken directly from the lesions, the picture became even clearer. They studied cells from a familial lesion and a sporadic one, comparing them to healthy cells. Both types of lesion cells showed a complete loss of the markers that define a healthy blood vessel. Instead, they began to produce proteins associated with a different, more mobile type of cell. This transformation was accompanied by a chaotic internal structure, with the cells' internal scaffolding becoming disorganized. The cells also grew faster and were harder to stop, indicating that they were in a state of uncontrolled expansion. Interestingly, the cells from the sporadic lesion showed a similar pattern to the familial ones, though perhaps slightly less advanced, suggesting that both forms of the disease follow the same biological path to destruction.
To see if this process could be halted, the researchers tested several existing drugs on the growing lesion cells. They focused on two main pathways that the cells seemed to be using to grow and survive. One set of drugs blocked a signaling system known to drive cell growth, while another set blocked a different pathway related to how the body responds to stress. Both approaches worked. The drugs significantly slowed down the growth of the lesion cells and reduced their ability to survive. This suggests that medications already approved for other conditions could potentially be repurposed to stabilize these brain lesions, offering a non-surgical option for patients who cannot undergo brain surgery or who have lesions that are too numerous to remove.
The study provides a detailed map of how cerebral cavernous malformations develop, moving from a subtle weakening of the vessel lining to a complete transformation of the cells. By showing that the disease starts with a loss of cellular identity and progresses into a state of uncontrolled growth, the researchers have identified specific targets for treatment. The fact that cells from both inherited and spontaneous cases behave similarly opens the door for therapies that could work for all patients, regardless of how they acquired the condition. While more work is needed to confirm these findings in humans, the ability to grow and test these patient cells offers a powerful new way to understand the disease and find ways to stop it before it causes a bleed.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.